State University of New York
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From State University of New York
Private Company Edition: Deerfield is funding a new life science campus. Also, BioFractura gets up to $67.4m in BARDA contract in recent grant and government deal surge, Mission Bay raises a $60m fund and Amphivena closes a $62m VC round.
Anyone who has ever taken a high-school science class has almost certainly been introduced to mitochondria as “the powerhouse of the cell, where energy is produced in the form of ATP.” MitoGenetics LLC believes it has identified a substance that can potentially fix things that start to break down in mitochondria as human cells age, and thereby restore normal cell function to reverse, or possibly even prevent, a great many diseases.
Start-Up's monthly comprehensive review of emerging life science companies that have received venture funding during the month, including companies in the pharmaceutical, medical device, diagnostic and research instrumentation and reagent sectors.
Nanobiotix is taking advantage of the ability of nanoparticles to absorb and transform energy to treat cancer. The company's nanoXray technology uses standard x-ray to activate injected cell-targeting non-drug nanoparticles. Today, Nanobiotix is focused solely on cancer applications of its technology, but the company believes there are other targets for the technology, including cardiovascular diseases.
- Academic and Research Institutions
- Other Names / Subsidiaries
- The State University of New York